Comment
doi: 10.1056/NEJMc1714339.
Nivolumab and Ipilimumab in Advanced Melanoma
Affiliations
- PMID: 29262279
- DOI: 10.1056/NEJMc1714339
Item in Clipboard
Comment
Nivolumab and Ipilimumab in Advanced Melanoma
N Engl J Med.
.
Erratum in
-
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.N Engl J Med. 2018 Nov 29;379(22):2185. doi: 10.1056/NEJMx180040. Epub 2018 Nov 9. N Engl J Med. 2018. PMID: 31442371 No abstract available.
No abstract available
Comment on
-
Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med. 2017 Dec 21;377(25):2503. doi: 10.1056/NEJMc1714339. N Engl J Med. 2017. PMID: 29265785 No abstract available.
-
Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med. 2017 Dec 21;377(25):2503. doi: 10.1056/NEJMc1714339. N Engl J Med. 2017. PMID: 29265786 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
